Neurological Disorders – Epilepsy Research

Hospital Ruber Internacional’s neurology team is advancing the treatment of epilepsy and related encephalopathies through studies that assess safety and seizure‑reduction potential of emerging medicines.

  • Adult focal (partial onset) epilepsy
  • Refractory focal onset epilepsy
  • Dravet syndrome and Lennox‑Gastaut syndrome
  • Developmental and epileptic encephalopathies (DEE)
  • Epilepsy associated with tuberous sclerosis complex
  • KCNT1‑related developmental encephalopathy

The goal is to improve seizure control and quality of life for patients with rare and treatment‑resistant seizure disorders.

Oncology – Melanoma Immunotherapy

In the oncology unit, investigators are evaluating a biosimilar to Opdivo for patients with advanced melanoma, focusing on comparable efficacy and safety.

  • Previously untreated unresectable melanoma
  • Metastatic stage III/IV melanoma
  • First‑line immunotherapy with nivolumab biosimilar

These trials aim to broaden access to effective immunotherapy options while maintaining clinical outcomes.

Oncology – Prostate Cancer Hormone Therapy

The department conducts research on prostate cancer to determine the optimal duration of androgen deprivation therapy combined with salvage radiotherapy after surgical recurrence.

  • Recurrent prostate cancer post‑prostatectomy
  • Short‑term versus long‑term ADT
  • Salvage radiotherapy integration

Findings are expected to refine treatment protocols and improve long‑term disease‑free survival.

Neurodegenerative – Early Parkinson’s Disease

Studies at the site explore disease‑modifying strategies for Early Parkinson’s Disease, measuring impact on functional scores such as the MDS‑UPDRS.

  • Early-stage Parkinson’s patients
  • Movement Disorder Society Unified Parkinson’s Disease Rating Scale outcomes
  • Time to first worsening event

The research seeks to delay progression and maintain daily living abilities for individuals newly diagnosed with Parkinson’s.

Rare Genetic & Congenital Disorders

A dedicated program investigates therapies for congenital, hereditary and neonatal neurological conditions, targeting specific genetic mutations that drive severe seizure phenotypes.

  • KCNT1‑related developmental and epileptic encephalopathy
  • Other rare developmental encephalopathies
  • Genetically driven seizure disorders

By focusing on precision medicine, the trials aim to deliver targeted treatments that address the underlying genetic causes.